

# EUROPEAN RESPIRATORY journal

FLAGSHIP SCIENTIFIC JOURNAL OF ERS

Early View

Original article

# Patterns and determinants of exhaled nitric oxide trajectories in schoolchildren over a 7-year period

Erika Garcia, Yue Zhang, Edward B. Rappaport, Kiros Berhane, Patrick Muchmore, Philip E. Silkoff, Noa Molshatzki, Frank D. Gilliland, Sandrah P. Eckel

Please cite this article as: Garcia E, Zhang Y, Rappaport EB, *et al*. Patterns and determinants of exhaled nitric oxide trajectories in schoolchildren over a 7-year period. *Eur Respir J* 2020; in press (https://doi.org/10.1183/13993003.00011-2020).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020

### Title

Patterns and determinants of exhaled nitric oxide trajectories in schoolchildren over a 7-year period

# Authors

Erika Garcia<sup>1</sup>

Yue Zhang<sup>2</sup>

Edward B. Rappaport<sup>1</sup>

Kiros Berhane<sup>1</sup>

Patrick Muchmore<sup>1</sup>

Philip E Silkoff<sup>3</sup>

Noa Molshatzki<sup>1</sup>

Frank D. Gilliland<sup>1</sup>

Sandrah P. Eckel<sup>1</sup>

## Affiliations

<sup>1</sup>Department of Preventive Medicine, Keck School of Medicine, University of Southern California,

Los Angeles, CA, USA

<sup>2</sup>Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA

<sup>3</sup>Philadelphia, PA

#### **Corresponding author**

Sandrah P. Eckel

USC Department of Preventive Medicine

2001 N. Soto Street, SSB 202B, MC-9234

Los Angeles, CA 90089

Email: <u>eckel@usc.edu</u>

Phone: (323) 442-2030

Fax: (323) 442-2349

# Take home message of paper

Longitudinal  $F_ENO_{50}$  trajectories in healthy children ages 8-16 displayed a similar upward trend in males and females until age 11.5, after which males had higher  $F_ENO_{50}$ . Males with higher starting BMI percentile had attenuated  $F_ENO_{50}$  slopes in age.

#### ABSTRACT

Fractional exhaled nitric oxide ( $F_ENO_{50}$ ), a marker of allergic airway inflammation, is used in respiratory research and asthma clinical care; however, its trajectory with increasing age during childhood has not been well characterized. We examined  $F_ENO_{50}$  longitudinally during a period of important somatic growth to describe trajectories across childhood and adolescence in healthy participants and evaluate clinical factors as potential determinants of trajectories.

 $F_ENO_{50}$  was collected at six visits over eight years in a population-based cohort of 1791 schoolchildren without asthma (median age at entry 8.4). Smooth sex-specific  $F_ENO_{50}$  trajectories were estimated using generalized additive mixed models, with participant-level random effects. We evaluated whether sex-specific trajectories were influenced by race/ethnicity, BMI percentile, allergic rhinitis, or puberty.

Different  $F_ENO_{50}$  patterns were observed by sex in later childhood and several factors were associated with either  $F_ENO_{50}$  level or change in  $F_ENO_{50}$  as participants aged.  $F_ENO_{50}$ -age trajectories were similar by sex until age ~11.5, after which males had greater  $F_ENO_{50}$  change than females. This divergence in  $F_ENO_{50}$ -age trajectories coincides with puberty. Males with higher starting BMI percentile had attenuated  $F_ENO_{50}$ -age slopes. Among males,  $F_ENO_{50}$  levels were lower in non-Hispanic Whites. Among both sexes, participants with rhinitis had higher  $F_ENO_{50}$ .  $F_ENO_{50}$  levels within individuals tracked over time; however, there was considerable variation in  $F_ENO_{50}$  patterns across participants.

 $F_ENO_{50}$  trajectories from longitudinal data provide evidence of sex differences coinciding with puberty, suggesting potential hormone link. Improved understanding of determinants of  $F_ENO_{50}$ trajectories is needed to realize the potential for using individualized predicted  $F_ENO_{50}$  trajectories.

#### Key words:

Adolescence, breath test, F<sub>E</sub>NO<sub>50</sub>, pediatric, reference value

#### Introduction

There is increasing evidence of the utility of fractional exhaled nitric oxide ( $F_ENO_{50}$ )—a noninvasive biomarker of allergic airway inflammation—for research, patient management of asthma treatment and in providing supporting evidence for asthma diagnosis [1-4]. Examining trends with age in  $F_ENO_{50}$  among healthy children during this critical period of growth as well as the impact of clinical factors such as sex, race/ethnicity, and allergic disease may enhance the utility of  $F_ENO_{50}$  in clinical and research settings.

Prior studies of the distribution and determinants of  $F_ENO_{50}$  in healthy pediatric populations were based on single cross-sectional measurements among children across a range of ages [5-11] which may have missed important patterns in  $F_ENO_{50}$  change as children grow. Serial measurements within the same set of children as they age is likely to be more informative for understanding trajectory of  $F_ENO_{50}$  across childhood and adolescence as well as potential determinants of this evolution. Furthermore, during childhood and adolescence there is an important epidemiological shift in the rates of allergic diseases, including asthma and allergic rhinitis, with higher rates among males during childhood, then in adolescence rates are higher among females—a reversal that maybe puberty related [12-14]. A better understanding of  $F_ENO_{50}$  trajectories coinciding with the timing of this transition is needed for improved use of  $F_ENO_{50}$  in research and clinical medicine.

The aim of this study was to examine  $F_ENO_{50}$  trajectories across childhood and adolescences in a unique data resource of healthy children from the Southern California Children's Health Study (CHS) with serial  $F_ENO_{50}$  measurements during a period of rapid somatic growth, ages 8-16 years. We investigate sex-specific  $F_ENO_{50}$  trajectories as a function of age and height, and evaluate potential determinants of  $F_ENO_{50}$  trajectories including race/ethnicity, body mass index (BMI), allergic rhinitis, and puberty.

#### Material and methods

#### Study design and study population

This study was performed within a cohort of the population-based CHS, described in detail previously [15]. Briefly, in 2002-2003, a prospective cohort of children primarily aged 6-7 years was enrolled from kindergarten and first grade public school classrooms from 13 communities. Follow-up for

 $F_ENO_{50}$  began in study year 3. Ethical approval of the protocol was obtained from the University of Southern California Institutional Review Board (approval # HS-13-00150, continuing review date April 17, 2019). Informed consent was obtained from a parent or guardian at first and follow-up visits through 2007-2008, and informed assent was obtained from each child at visits after 2008. Because the study aim was to examine  $F_ENO_{50}$  trajectories in healthy children, we excluded participants with any history of asthma based on all study questionnaire data (n=618). We sequentially excluded  $F_ENO_{50}$  measurements conducted when height was not recorded (29 observations), or the participant had reported respiratory infection within the past 3 days (389 observations), or the participant had reported personal smoking within the last month (56 observations). These last eligibility criteria excluded that year's  $F_ENO_{50}$  measurements and not the participants themselves, who could contribute  $F_ENO_{50}$  measurements in years when they met eligibility criteria for  $F_ENO_{50}$ measurements. The final study population consisted of 1791 healthy children with 7185  $F_ENO_{50}$ 

#### Measurement of Exhaled Nitric Oxide

 $F_ENO_{50}$  assessment in the CHS has been described in detail previously [16-18]. Briefly,  $F_ENO_{50}$  was collected at schools using an offline breath collection technique in years 3-4 at 100 mL/s flow using Sievers sampling kits and analyzed with a Sievers Model 280i NO analyzer, and online using ECO MEDICS CLD-88-SP instruments (with DeNOx) at 50mL/s flow during years 5, 6, 8, and 10 following manufacturers' instructions and professional societies guidelines [19, 20] (Table 1; additional details in eMethods). Offline  $F_ENO_{50}$  values were converted to online values at 50mL/s using a prediction model developed internally ( $R^2 = 0.94$ ) from a pilot study including concurrent offline and online measurements among 362 schoolchildren in 2006-2007 [17]. Prediction model inputs included offline  $F_ENO_{50}$ , ambient NO, and lag time before analysis [17]. Model-predicted online  $F_ENO_{50}$  estimates produced results similar to observed online  $F_ENO_{50}$  measures in analysis of school and age differences [17].

#### Covariate assessment

Parents/guardians completed written questionnaires at first and follow-up visits (children responded beginning year 8 when they were aged 13.5 years (standard deviation (SD):0.63) providing

information on child's sex, race/ethnicity, date of birth, allergic rhinitis, and history of doctordiagnosed asthma. Ever reported allergic rhinitis at year 3 was defined based on responses to the questions "has your child ever/in the past 12 months had a problem with sneezing or a runny or blocked nose, when he/she did not have a cold or the 'flu?'" and "in the past 12 months, has this nose problem been accompanied by itchy-watery eyes?" We categorized a positive response to both questions as "allergic rhinitis." Children were classified as having asthma if it was reported on any questionnaire that a doctor had "ever diagnosed this child as having asthma." Reported respiratory infection within the past 3 days was based on questionnaire data from parents (through year 6) or participants (years 8 and 10). Starting year 6, children were asked about personal smoking (cigarettes or anything else) [15, 18]. Height and weight measurements were used to calculate age- and sexspecific BMI percentiles (BMI%) from the Centers for Disease Control and Prevention growth charts [21]. Height velocity was calculated as the difference in height divided by the difference in age between consecutive annual study visits. Age at peak height velocity—a proxy for puberty [22]—was then determined and subsequently categorized as "early" or "late" based on sex-specific median. *Statistical analysis* 

 $F_ENO_{50}$  values are right skewed. Therefore, unless otherwise specified, we performed analyses with natural log-transformed  $F_ENO_{50}$  (log $F_ENO_{50}$ ), with results presented using back-transformed values. Analyses were stratified by sex *a priori*, based on reported differences in  $F_ENO_{50}$  between male and female children [5].

Descriptive analyses present study population characteristics and describe sex-specific associations of these characteristics with year 3  $F_ENO_{50}$  in the subset of n=1429 participants with available  $F_ENO_{50}$  and with percent change in  $F_ENO_{50}$  from year 3 (median age 8.4 years [interquartile range [IQR]: 7.9-8.9) to year 10 (median age 15.3 years [IQR:14.7-15.8]) in the subset of n=681 children with  $F_ENO_{50}$  measured in both years. Percent change relates the geometric mean of  $F_ENO_{50}$  at year 10 to the geometric mean of  $F_ENO_{50}$  at year 3 (i.e., exponentiated mean difference in  $\log F_ENO_{50}$  from year 3 to 10). We evaluated statistical significance of differences between categorical covariates for year 3  $F_ENO_{50}$  using one-way analysis of variance and for year 3 to 10  $F_ENO_{50}$  percent change using a non-parametric Kruskal-Wallis test. To quantify the correlation of repeated, longitudinal measurements of

 $logF_ENO_{50}$  in participants over the 8-year period, we calculated intraclass correlation coefficients (ICC).

Sex-specific  $F_{\rm F}NO_{50}$  trajectories as function of age and/or height were modeled by fitting generalized additive mixed models [23, 24], with a participant-level random intercept and random slope on age (or on height for height-only model), to all available data on the 1791 participants using the R package 'mgcv' [24]. Smooth functions of only height or only age were fitted using a penalized regression spline [24]. A joint smooth function of age and height was fitted using a penalized tensor product smooth [24]. Next, using data on 1717 participants with complete year 3 BMI%, we evaluated whether sex-specific age trajectories were influenced by: (a) year 3 BMI%, (b) race/ethnicity (Hispanic, White/non-Hispanic, other (includes missing)), or (c) year 3 ever reported allergic rhinitis (yes, no, missing), using parameterizations that allowed for quantification of age interactions (see online supplement eMethods). Based on statistical significance in bivariate analyses, final models for  $F_{\rm E}NO_{50}$ -age trajectories were then developed. Lastly, we stratified final models by dichotomized (early or late) age at peak height velocity as a proxy for puberty. Sensitivity analysis included analyses: (i) with height instead of age trajectories, (ii) with time-varying BMI% collected over follow-up instead of year 3 BMI%, (iii) restricted to 1062 children who never reported allergic rhinitis through year 10, (iv) restricted to 1526 children who never reported wheeze or whistling in the chest through year 10, and (v) restricted to online F<sub>E</sub>NO<sub>50</sub> measurements only. All statistical analyses were performed using R 3.5.1 [25].

#### Results

Participants' mean age was 8.4 years (SD: 0.65) in study year 3, the initial year of  $F_ENO_{50}$  follow up. In year 3 (n=1429), geometric mean  $F_ENO_{50}$  was 10.6 parts per billion (ppb) (geometric SD: 1.84), with no difference by sex (p=0.90). Median follow-up time from first to last  $F_ENO_{50}$  measurement was 5.2 years (interquartile range: 2.0-6.8) and 46.6% of participants had 5 or 6  $F_ENO_{50}$  measurements (mean: 4.0; Table E1). See Figure E1 for example trajectories. The ICC was 0.57 for males and 0.59 for females, indicating moderately strong within-participant correlation of  $F_ENO_{50}$ .  $F_ENO_{50}$  generally increased from year 3 to 10. Percent change in  $F_ENO_{50}$  from year 3 to 10 in the n=681 children with available data, was higher in males than females (53.2% vs 14.4%, respectively, p<0.001). There were no statistically significant differences in covariate distributions between participants with and without year 10 data (Table E1).

In descriptive analyses, determinants of year 3  $F_ENO_{50}$  were different from determinants of  $F_ENO_{50}$  change from year 3 to 10 as shown in Tables 2a (males) and Table 2b (females). In year 3,  $F_ENO_{50}$  was statistically significantly different by race/ethnicity for males and by age and allergic rhinitis for females. From year 3 to 10, there was modest evidence for differences in percent change in  $F_ENO_{50}$  by year 3 BMI% in males (p=0.07), with an attenuated increase in  $F_ENO_{50}$  for those with higher year 3 BMI%. Among females, percent change in  $F_ENO_{50}$  differed by age and height in year 3, with larger  $F_ENO_{50}$  change among those younger or shorter in year 3.

Estimates of population-averaged sex-specific trajectories of  $F_ENO_{50}$  by age and/or height (n=1791) are displayed in Figure 1 and summarized in Table E2. As a function of age, estimated geometric mean  $F_ENO_{50}$  at age 8 was similar by sex (10.6 and 10.7 ppb for males and females, respectively) and the nonlinear  $F_ENO_{50}$  trajectory was similar by sex through approximately age 11.5. After age 11.5, males tended to have a larger increase in  $F_ENO_{50}$  than females. By age 15, predicted geometric mean  $F_ENO_{50}$  for an average male was 16.5 (95%CI: 15.4, 17.6) ppb and for an average female 12.6 (11.9, 13.4) ppb. This translates to an increase from age 8 to 15 of 54.9% (44.8, 65.8) for the average male and 17.8% (11.0, 25.0) for the average female. As a function of height,  $F_ENO_{50}$  trajectory for an average child was nearly linear for males and nonlinear, with a shallower slope for females. When considering joint smooths of age and height, there was evidence of an interaction (Figure 1c-d, Table E2). For example, for females (Figure 1d) the positive association between age and  $F_ENO_{50}$  was attenuated for taller younger females (approximately height>140 cm, age <13) and negative for taller older females (approximately height>140 cm, age ≥13).

There was considerable between-participant heterogeneity (i.e., nonuniformity) as shown in the participant-specific predicted trajectories (Figure 2). To put estimated random intercept SDs into context (males: 0.50; females: 0.47 (logF<sub>E</sub>NO<sub>50</sub> scale)), estimated average  $F_ENO_{50}$  for males at age 8 was 10.6 ppb, but with a 95% CI that ranged from 4.0 ppb to 28.2 ppb (exp(2.36±1.96\*0.50)). Subsequent "tracking" of participant-specific predicted trajectories is apparent in Figure 2, with participants with high (or low)  $F_ENO_{50}$  at start of follow up generally having high (or low)  $F_ENO_{50}$ 

through end of follow up. There was also considerable heterogeneity in the random slopes on age (SD: males: 0.051; females: 0.052). For context, linear mixed effects models assuming a linear (rather than smooth) trajectory of  $\log F_E NO_{50}$  in age had population average slopes on age of 0.061 for males and 0.022 for females.

The estimated sex-specific age trajectories of F<sub>E</sub>NO<sub>50</sub> by categories of sex, race/ethnicity, and allergic rhinitis, and year 3 BMI% (n=1717) are displayed in Figure 3 and summarized in Tables 3 and E3. The only covariate that significantly modified the average  $F_ENO_{50}$ -age trajectory (i.e.,  $F_ENO_{50}$  change from age 8 to 16 years) was year 3 BMI% in males. Males with higher year 3 BMI% had a lower rate of  $F_{\rm E}NO_{50}$  increase than males with lower BMI (interaction p=0.009) as demonstrated in Figures 3 and E3c-d. Year 3 allergic rhinitis in both sexes and race/ethnicity in males shifted the intercept of, but did not modify,  $F_ENO_{50}$ -age trajectories. At any given age, children reporting allergic rhinitis ever in year 3 had higher  $F_{\rm F}NO_{50}$  (p<0.001) and  $F_{\rm F}NO_{50}$  was higher for males in the "Other" race/ethnicity group (composed of Black, Asian, other and missing) than in the Hispanic group (p=0.02). Finally, we estimated sex-specific models including the joint smooth function of age and year 3 BMI% and main effects of race/ethnicity and year 3 allergic rhinitis. Associations were similar to those reported in models including one covariate at a time (Table 3). Predictions for participants with selected covariate values are provided in Table E4 to demonstrate the range of F<sub>E</sub>NO<sub>50</sub> values and rates of change over time. Despite statistically significant evidence for covariate associations with F<sub>E</sub>NO<sub>50</sub> levels and trajectories, inclusion of the three covariates in the final model did not considerably reduce the SD of the random intercept (males: 0.49; females: 0.47) or random slope (males: 0.049; females: 0.052), nor did it improve model fit based on Bayesian Information Criterion (BIC) (Table E3).

Analyses stratifying  $F_ENO_{50}$  trajectories by age at peak height velocity reduced the sample size to 611 participants due to insufficient height data needed to identify age at peak height velocity; sex-specific  $F_ENO_{50}$ -age trajectories, however, were similar in this subset compared with the full study population (Figure E2). Separation in  $F_ENO_{50}$  trajectories between males and females occurred at younger ages among children with early age at peak height velocity and at older ages among children with late age at peak height velocity (Figure 4 and Table E5).

The main findings of diverging  $F_ENO_{50}$  trajectories between males and females in later childhood and attenuated  $F_ENO_{50}$  trajectory slopes for males with higher year 3 BMI% were robust in sensitivity analyses (trajectories in height rather than age, Table E6 and Figure E3; trajectories in age using timevarying BMI% instead of year 3 BMI%, Figure E4; trajectories in age in children without allergic rhinitis, Figures E5-E6; trajectories in age in children without wheeze or whistling in the chest, Figures E7-E8; and restricting to online  $F_ENO_{50}$  measurements, Figures E9-E10). Although year 3 BMI% did not reach statistical significance as a modifier of  $F_ENO_{50}$  trajectories when restricting to online  $F_ENO_{50}$  measurements, the patterns observed by year 3 BMI% was similar for the overlapping ages in the two analyses (~10 to ~16). Additionally, we further excluded  $F_ENO_{50}$  observations with reported respiratory infection in the last month and results were not markedly different (data not shown).

#### Discussion

Using repeated F<sub>E</sub>NO<sub>50</sub> measurements from a large, population-based sample of healthy children during a period of prepubescent/pubescent growth (median starting age 8.4 years through median age at end of follow up 15.3 years), we report longitudinal evidence that on average F<sub>E</sub>NO<sub>50</sub> increased nonlinearly with age, with larger increases in males than females at older ages. Interestingly, when stratified by early or late age at peak height velocity, this departure in F<sub>E</sub>NO<sub>50</sub> trajectories between the sexes shifted to younger or older ages coinciding with early/later estimated timing of puberty. Additionally, males with higher year 3 BMI% had attenuated F<sub>E</sub>NO<sub>50</sub> slopes in age and race/ethnicity in males and year 3 allergic rhinitis in both sexes affected F<sub>E</sub>NO<sub>50</sub> level but did not have impact on F<sub>E</sub>NO<sub>50</sub> trajectories. We also observed considerable unexplained variation in F<sub>E</sub>NO<sub>50</sub> level and  $F_{\rm F}NO_{50}$  change across age between children (large SD of random intercept and slope). Longitudinal trends in F<sub>E</sub>NO<sub>50</sub> among children as they age observed in this study confirm reports of age association from previous cross-sectional studies in children and adolescents [5, 7, 10, 26]. Combining both sexes, linear increases in F<sub>E</sub>NO<sub>50</sub> were reported by Buchvald et al. over ages 4-17 [7] and Yao et al. over ages 5-18 [26], while Jacinto et al. reported linear increases in  $F_ENO_{50}$  through 14.1 years old in females and 15.7 years in males, after which point  $F_ENO_{50}$  levels plateaued until late middle age [5]. Brody et al. reported no difference in F<sub>E</sub>NO<sub>50</sub> levels for males and females ages 6-11

years, but at ages 12-19 females had lower F<sub>E</sub>NO<sub>50</sub> levels than males [10]. The F<sub>E</sub>NO<sub>50</sub> levels reported here are slightly larger compared with these earlier studies, but this may be due in part to the large percentage (69%) of non-White participants (see discussion below regarding race/ethnicity and  $F_{E}NO_{50}$ ). Overall, these earlier studies are generally consistent with our findings that males and females have similar F<sub>E</sub>NO<sub>50</sub> trajectories until early adolescence, after which males exhibit continued increases while females appear to plateau. Somatic growth and the increase in anatomic dead space volume may be a biological rationale for increases in  $F_{\rm E}NO_{50}$  with age and differences between males and females in later childhood [5]. Development and growth of the bronchial tree leads to larger total airway mucosal surface area available for NO diffusion, thus higher  $F_ENO_{50}$  [5]. Potential impacts of alveolar growth on F<sub>E</sub>NO<sub>50</sub> trajectories could be investigated in future studies of alveolar versus airway NO concentrations [27, 28]. Although we did not have data on pubertal staging for participants, we were able to use a proxy for puberty-age at peak height velocity-to assign children as either early or late "maturers." Timing of divergence between the sexes in F<sub>E</sub>NO<sub>50</sub> trajectories corresponded with this estimate of early versus late onset of puberty. Sex hormones have been suggested by animal studies to be involved in mechanisms of lung inflammation and asthma [29], with ovarian hormones found to increase and testosterone found to decrease airway inflammation in asthma; however, there are discrepancies between experimental and epidemiologic studies [14]. The mechanism by which puberty may affect  $F_{\rm E}NO_{50}$  trajectories is unclear but may shed light on sex differences trends in asthma and other allergic diseases.

With these longitudinal data, we were able to observe differences in  $F_ENO_{50}$  slopes by BMI% among male children, with participants with higher year 3 BMI% having attenuated  $F_ENO_{50}$  slopes which persisted after controlling for race/ethnicity and year 3 allergic rhinitis. Differences in slope are primarily observed in earlier ages (8-10 years). This pattern was observed both for year 3 BMI% and time-varying BMI%. Previous studies have found no association between  $F_ENO_{50}$  in children and weight [6-8], body surface area [8], or BMI [7, 10, 30], with exception of a reported negative association with BMI z-score, primarily in atopic children [31] and weak positive correlation for body surface area [7]. BMI%, which is considered in the present study, may better represent being under/over-weight at a given age and sex. Furthermore, the longitudinal associations we examinedthe impact of prepubescent BMI% on  $F_ENO_{50}$  trajectory during adolescence—may differ from crosssectional associations. A recent study found individuals with higher BMI to have greater adipose tissue area within airway walls and greater airway wall thickness [32]. This structural change in the airways could potentially impact airway NO production/diffusion as well as  $F_ENO_{50}$  measured at the mouth.

We also observed an association between allergic rhinitis and  $F_ENO_{50}$ , which is supported by the literature [7, 8, 33, 34], although some studies report no association [6]. Some studies of  $F_ENO_{50}$  in healthy children exclude those with reported rhinitis [34], but results were similar in our sensitivity analyses excluding children with allergic rhinitis.

Non-Hispanic white males had lower  $F_ENO_{50}$  levels across age compared with Hispanic and all other race males. Similar patterns were observed for females, but results did not reach statistical significance. Evidence from cross-sectional studies supports an association between race/ethnicity and  $F_ENO_{50}$ . A 2017 review reported that among eight studies with children, seven found race/ethnicity to be a significant influencing factor for  $F_ENO_{50}$ , with six observing higher  $F_ENO_{50}$  levels in the non-Caucasian ethnic groups (including African American, Hispanic, and Asian) compared with Caucasian levels [35]. Higher  $F_ENO_{50}$  has been reported in non-Hispanic blacks and Hispanics compared to non-Hispanic whites among children in the U.S. aged 6-19 years [10]. In a separate study, non-Caucasian subjects (African American, Asian, and Hispanic subjects) had higher  $F_ENO_{50}$ compared with Caucasian subjects, but this difference was only borderline significant after controlling for age, sex, and self-reported atopy [7]. Whether differences are driven by genetic versus contextual factors is unclear and warrants further investigation.

This study has limitations. First, the age range is limited thus it is unclear whether differences between males and females persist into early adulthood. Second, due to budgetary constraints  $F_ENO_{50}$ assessments were conducted every two years in years 6-10; however, because there was a range of ages at study entry inference regarding  $F_ENO_{50}$  trajectory in early and mid-teenage years are wellsupported by the data. Third, the first two years of  $F_ENO_{50}$  data (years 3 and 4) were collected using offline methods, while  $F_ENO_{50}$  data for the remainder of the study (years 5-10) were collected using online methods. Although offline  $F_ENO_{50}$  measurement were converted to online values based on a published internally-developed prediction model with an  $R^2 = 0.94$  [17], there remains a possibility that this change in breath collection technique during the study could influence F<sub>E</sub>NO<sub>50</sub> trajectories in age, especially for estimated trajectories around ages 9-10 years when the change in collection method occurred which coincides with an apparent attenuate in  $F_ENO_{50}$  slope. However, in sensitivity analyses restricted to online F<sub>E</sub>NO<sub>50</sub> measurements, patterns in F<sub>E</sub>NO<sub>50</sub> trajectories, including the divergence between the sexes in later childhood, were similar to those in the main analysis, although the attenuation in slope around ages 9-11 years was less evident and remained only for males. The only other difference was in the findings for year 3 BMI%, which is likely due to lack of data in younger ages—the age period when  $F_{E}NO_{50}$  slope was most different by BMI% in the main analysis. Fourth, guidelines have been updated after the conclusion of data collection, but these would not have substantively impacted our F<sub>E</sub>NO<sub>50</sub> collection protocol [36]. Last, an objective measure of atopy (e.g., skin prick test, IgE sensitization) was not available and we instead relied on questionnaire assessment of allergic rhinitis. IgE sensitization may be present without obvious symptoms and may still cause increased F<sub>E</sub>NO<sub>50</sub> but would not have been captured by our classification of allergic rhinitis. Without such data we were unable to investigate the potential for effect modification by atopy. This study has several strengths. First, we leveraged a large unique longitudinal data resource to be the first study to use serial measurements to examine  $F_ENO_{50}$ -age trajectories in healthy children. Second, F<sub>E</sub>NO<sub>50</sub> trajectories are investigated during an important period of growth for children. Last, the study population is diverse, with over 50% Hispanic, allowing for identification of racial/ethnic

differences in F<sub>E</sub>NO<sub>50</sub>-age trajectories.

In conclusion, we reported novel longitudinal evidence for nonlinear trajectories of  $F_ENO_{50}$  in healthy children followed from ages ~8 to ~15 years, with differences in trajectories by sex coinciding with puberty and prepubescent BMI%, and differences in level by allergic rhinitis and race/ethnicity. The considerable remaining unexplained between-child variability in trajectories highlights the limitations of fixed  $F_ENO_{50}$  reference values. As such, our results are not intended as reference growth curves, but to provide information on population average  $F_ENO_{50}$  trajectories in healthy children during a period of growth. However, the moderately strong within-participant correlation of  $F_ENO_{50}$  over an 8year period suggests that tracking personalized  $F_ENO_{50}$  measurements over time (to exploit this high within-participant correlation) may maximize the clinical utility of  $F_ENO_{50}$  measurements [37, 38].

#### Acknowledgements

We thank the participating students and their families, the school staff and administrators, and the study field team for their efforts.

### Funding

This work was supported by the National Heart, Lung and Blood Institute (grants R01HL61768 and R01HL76647); the Southern California Environmental Health Sciences Center (grant P30ES007048) funded by the National Institute of Environmental Health Sciences; the Children's Environmental Health Center (grants P01ES009581, R826708-01 and RD831861-01) funded by the National Institute of Environmental Health Sciences and the Environmental Protection Agency; the National Institute of Environmental Health Sciences (grants P01ES011627, R01ES023262, R01ES027860, and T32ES013678); the James H. Zumberge Research and Innovation Fund, and the Hastings Foundation.

#### References

1. Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. *Clin Exp Allergy* 2005: 35(9): 1175-1179.

2. Mahr TA, Malka J, Spahn JD. Inflammometry in pediatric asthma: a review of fractional exhaled nitric oxide in clinical practice. *Allergy Asthma Proc* 2013: 34(3): 210-219.

3. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels for Clinical A. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* 2011: 184(5): 602-615.

4. American Thoracic S, European Respiratory S. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005: 171(8): 912-930.

5. Jacinto T, Malinovschi A, Janson C, Fonseca J, Alving K. Evolution of exhaled nitric oxide levels throughout development and aging of healthy humans. *J Breath Res* 2015: 9(3): 036005.

6. Mallol J, Aguirre V, Cordova P, Cortez E, Gallardo A, Riquelme C. Fraction of exhaled nitric oxide in healthy Chilean schoolchildren aged 8-15 years. *Allergol Immunopathol (Madr)* 2015: 43(6): 528-532.

 Buchvald F, Baraldi E, Carraro S, Gaston B, De Jongste J, Pijnenburg MW, Silkoff PE,
 Bisgaard H. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. *J Allergy Clin Immunol* 2005: 115(6): 1130-1136.

8. Malmberg LP, Petays T, Haahtela T, Laatikainen T, Jousilahti P, Vartiainen E, Makela MJ. Exhaled nitric oxide in healthy nonatopic school-age children: determinants and height-adjusted reference values. *Pediatr Pulmonol* 2006: 41(7): 635-642.

9. Rouatbi S, Alqodwa A, Ben Mdella S, Ben Saad H. Fraction of exhaled nitric oxide (FeNO ) norms in healthy North African children 5-16 years old. *Pediatr Pulmonol* 2013: 48(10): 981-995.

10. Brody DJ, Zhang X, Kit BK, Dillon CF. Reference values and factors associated with exhaled nitric oxide: U.S. youth and adults. *Respir Med* 2013: 107(11): 1682-1691.

11. Hogman M, Thornadtsson A, Liv P, Hua-Huy T, Dinh-Xuan AT, Tufvesson E, Dressel H, Janson C, Koskela K, Oksa P, Sauni R, Uitti J, Moilanen E, Lehtimaki L. Effects of growth and aging on the reference values of pulmonary nitric oxide dynamics in healthy subjects. *J Breath Res* 2017: 11(4): 047103.

12. Almqvist C, Worm M, Leynaert B, working group of GALENWPG. Impact of gender on asthma in childhood and adolescence: a GA2LEN review. *Allergy* 2008: 63(1): 47-57.

13. Pinart M, Keller T, Reich A, Frohlich M, Cabieses B, Hohmann C, Postma DS, Bousquet J, Anto JM, Keil T. Sex-Related Allergic Rhinitis Prevalence Switch from Childhood to Adulthood: A Systematic Review and Meta-Analysis. *Int Arch Allergy Immunol* 2017: 172(4): 224-235.

14. Naeem A, Silveyra P. Sex Differences in Paediatric and Adult Asthma. *Eur Med J (Chelmsf)*2019: 4(2): 27-35.

McConnell R, Berhane K, Yao L, Jerrett M, Lurmann F, Gilliland F, Kunzli N, Gauderman J,
 Avol E, Thomas D, Peters J. Traffic, susceptibility, and childhood asthma. *Environ Health Perspect* 2006: 114(5): 766-772.

16. Bastain TM, Islam T, Berhane KT, McConnell RS, Rappaport EB, Salam MT, Linn WS, Avol EL, Zhang Y, Gilliland FD. Exhaled nitric oxide, susceptibility and new-onset asthma in the Children's Health Study. *Eur Respir J* 2011: 37(3): 523-531.

17. Linn WS, Berhane KT, Rappaport EB, Bastain TM, Avol EL, Gilliland FD. Relationships of online exhaled, offline exhaled, and ambient nitric oxide in an epidemiologic survey of schoolchildren. *J Expo Sci Environ Epidemiol* 2009: 19(7): 674-681.

18. Linn WS, Rappaport EB, Berhane KT, Bastain TM, Avol EL, Gilliland FD. Exhaled nitric oxide in a population-based study of southern California schoolchildren. *Respir Res* 2009: 10: 28.

19. ATS (American Thoracic Society). Recommendations for standardized procedures for the online and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* 1999: 160(6): 2104-2117.

20. ATS/ERS (American Thoracic Society and the European Respiratory Society). ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005: 171(8): 912-930.

21. Centers for Disease Control and Prevention (CDC). A SAS program for the CDC growth charts. 2009.

22. Kelly A, Winer KK, Kalkwarf H, Oberfield SE, Lappe J, Gilsanz V, Zemel BS. Age-based reference ranges for annual height velocity in US children. *J Clin Endocrinol Metab* 2014: 99(6): 2104-2112.

23. Wood SN. Stable and efficient multiple smoothing parameter estimation for generalized additive models. *Journal of the American Statistical Association* 2004: 99(467): 673-686.

24. Wood SN. Generalized additive models: an introduction with R. CRC press, 2017.

25. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2018.

26. Yao TC, Lee WI, Ou LS, Chen LC, Yeh KW, Huang JL, Group PS. Reference values of exhaled nitric oxide in healthy Asian children aged 5 to 18 years. *Eur Respir J* 2012: 39(2): 378-384.

27. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. *J Appl Physiol* (1985) 2004: 96(3): 831-839.

28. Hogman M. Extended NO analysis in health and disease. *J Breath Res* 2012: 6(4): 047103.

29. Yung JA, Fuseini H, Newcomb DC. Hormones, sex, and asthma. *Ann Allergy Asthma Immunol* 2018: 120(5): 488-494.

30. Kovesi T, Kulka R, Dales R. Exhaled nitric oxide concentration is affected by age, height, and race in healthy 9- to 12-year-old children. *Chest* 2008: 133(1): 169-175.

31. Yao TC, Tsai HJ, Chang SW, Chung RH, Hsu JY, Tsai MH, Liao SL, Hua MC, Lai SH, Chen LC, Yeh KW, Tseng YL, Lin WC, Chang SC, Huang JL, Prediction of Allergies in Taiwanese Children Study G. Obesity disproportionately impacts lung volumes, airflow and exhaled nitric oxide in children. *PLoS One* 2017: 12(4): e0174691.

32. Elliot JG, Donovan GM, Wang KCW, Green FHY, James AL, Noble PB. Fatty Airways: Implications for Obstructive Disease. *Eur Respir J* 2019.

33. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D. Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. *Clin Exp Allergy* 2003: 33(11): 1506-1511.

34. Jacinto T, Alving K, Correia R, Costa-Pereira A, Fonseca J. Setting reference values for exhaled nitric oxide: a systematic review. *Clin Respir J* 2013: 7(2): 113-120.

35. Blake TL, Chang AB, Chatfield MD, Petsky HL, Rodwell LT, Brown MG, Hill DC, McElrea MS. Does Ethnicity Influence Fractional Exhaled Nitric Oxide in Healthy Individuals?: A Systematic Review. *Chest* 2017: 152(1): 40-50.

36. Horvath I, Barnes PJ, Loukides S, Sterk PJ, Hogman M, Olin AC, Amann A, Antus B, Baraldi E, Bikov A, Boots AW, Bos LD, Brinkman P, Bucca C, Carpagnano GE, Corradi M, Cristescu S, de Jongste JC, Dinh-Xuan AT, Dompeling E, Fens N, Fowler S, Hohlfeld JM, Holz O,

Jobsis Q, Van De Kant K, Knobel HH, Kostikas K, Lehtimaki L, Lundberg J, Montuschi P, Van Muylem A, Pennazza G, Reinhold P, Ricciardolo FLM, Rosias P, Santonico M, van der Schee MP, van Schooten FJ, Spanevello A, Tonia T, Vink TJ. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. *Eur Respir J* 2017: 49(4).

37. Ferrante G, Malizia V, Antona R, Corsello G, Grutta S. The value of FeNO measurement in childhood asthma: uncertainties and perspectives. *Multidiscip Respir Med* 2013: 8(1): 50.

Holz O, Magnussen H. Cutoff values for FENO-guided asthma management. *Am J Respir Crit Care Med* 2009: 180(3): 281-282; author reply 282.

#### **Figure Legends**

**Figure 1.** Population-averaged sex-specific trajectories of fractional exhaled nitric oxide ( $F_ENO_{50}$ ) (solid lines) (N=851 males, N=940 females) and 95% Confidence Intervals (dashed lines) modeled as a: (a) smooth function of age only, (b) a smooth function of height only, or a joint smooth of age and height for males (c) or females (d). In panels (c-d), the contour lines labels refer to predicted geometric mean  $F_ENO_{50}$  in ppb. Analyses performed using  $logF_ENO_{50}$  with results here presented using back-transformed values on an axis scaled using natural log.

**Figure 2.** Participant-specific predicted trajectories of fractional exhaled nitric oxide ( $F_ENO_{50}$ ), modeled as a smooth function of age, for 40 randomly selected males and 40 randomly selected females. Analyses performed using  $logF_ENO_{50}$  with results here presented using back-transformed values on an axis scaled using natural log. The population average predictions (identical to Figure 1a) are plotted with a heavy black line.

**Figure 3.** Modeled sex-specific trajectory of fractional exhaled nitric oxide ( $F_ENO_{50}$ ) (N=809 males, N=908 females) as a joint smooth of age and year 3 body mass index percentile or as smooths of age that vary by race/ethnicity or ever reported allergic rhinitis in year 3. Analyses performed using  $logF_ENO_{50}$  with results here presented using back-transformed values on an axis scaled using natural log.

**Figure 4.** Modeled sex-specific trajectory of fractional exhaled nitric oxide ( $F_ENO_{50}$ ) (N=288 males, N=323 females) as a joint smooth of age that vary by early (solid line) or late (dashed line) age at peak height velocity for males (blue) and females (yellow). Sex-specific models including a joint smooth of age and year 3 body mass index percentile by category of age at peak height velocity and adjustments for race/ethnicity and year 3 allergic rhinitis status. Grey bars at bottom is histogram of age.

# Tables

**Table 1.** Study design information including type and number of  $F_ENO_{50}$  measurements and average participant age over the study period. Over the entire study period 1791 children contributed  $F_ENO_{50}$  measurements.

Study Year	1	2	3*	4	5	6	8	10		
Calendar Years	2002-03	2003-04	2004-05	2005-06	2006-07	2007-08	2009-10	2011-12		
F <sub>E</sub> NO <sub>50</sub> measure type	No	None Offline				Online				
Participants with			1429	1498	1364	1100	938	856		
F <sub>E</sub> NO <sub>50</sub> data (N)										
Mean age (years)			8.4	9.3	10.3	11.4	13.5	15.3		

No  $F_E NO_{50}$  data collected study years 1 and 2.

No follow-up,  $F_ENO_{50}$  or otherwise, conducted in study years 7 (2008-09) or 9 (2010-11) \*The start of follow up for the current study

Year 3	unge m	1 E1 (030 0	ver uppron	Year	$3 F_E NO_{50}$	%	Change in	n F <sub>E</sub> NO <sub>50</sub> , ye	ear 3 to 10
Characteristic					(N=672)		0	2 00/0	(N=318)
			Geometri	ic	р-				р-
	Ν	(%)	mean		value*	Ν	(%)	Estimate	value†
Age, years					0.178				0.749
7	48	(7%)		9.2		25	(8%)	60.4	
8	313	(47%)		10.3		144	(45%)	52.1	
9	276	(41%)		11.0		133	(42%)	56.5	
10	35	(5%)		11.6		16	(5%)	26.8	
Height, cm					0.140				0.816
≤125	129	(19%)		9.9		50	(16%)	56.7	
(125, 130]	168	(25%)		10.9		73	(23%)	46.1	
(130, 135]	205	(31%)		10.1		114	(36%)	60.7	
>135	170	(25%)		11.4		81	(25%)	47.2	
BMI percentile					0.957				0.067
0-15	41	(6%)		10.4		22	(7%)	45.6	
15-85	359	(53%)		10.7		169	(53%)	68.2	
85-95	122	(18%)		10.6		61	(19%)	44.5	
95+	150	(22%)		10.4		66	(21%)	29.3	
Race/ethnicity					< 0.001				0.468
Hispanic	386	(57%)		11.0		177	(56%)	62.9	
White/non-Hispanic	226	(34%)		9.5		115	(36%)	48.2	
Black	12	(2%)		10.4		4	(1%)	67.0	
Asian	27	(4%)		18.1		11	(3%)	28.4	
Other	19	(3%)		8.0		10	(3%)	72.2	
Missing	2	(0.3%)		17.1		1	(0.3%)	-35.4	
Ever reported allergic					0.109				0.779
rhinitis									
No	380	(57%)		10.2		180	(57%)	51.2	
Yes	193	(29%)		11.5		94	(30%)	57.7	
Missing	99	(15%)		10.3		44	(14%)	51.5	

Table 2a. For males, participant characteristics at year 3 and associations with fractional exhaled nitric oxide  $(F_ENO_{50})$  or percent change in  $F_ENO_{50}$  over approximately 7 years.

\* Analysis of variance (ANOVA) F-test (excluding missing categories, if applicable)
† Kruskal-Wallis test, a non-parametric alternative to ANOVA (excluding missing categories, if applicable)

Year 3		E1 ( 0 30 0 1)	Year	$3 F_E NO_{50}$	%	6 Change	in F <sub>E</sub> NO <sub>50</sub> , y	ear 3 to 10
Characteristic				(N=757)		8	E 5077	(N=363)
			Geometric	. ,				<u>, , , , , , , , , , , , , , , , , , , </u>
	Ν	(%)	mean	p-value*	Ν	(%)	Estimate	p-value†
Age, years				0.001		· · ·		0.069
7	65	(9%)	8.7		33	(9%)	34.5	
8	381	(50%)	10.3		179	(49%)	18.6	
9	288	(38%)	11.7		136	(37%)	4.3	
10	23	(3%)	10.0		15	(4%)	22.1	
Height, cm				0.166				0.040
≤125	202	(27%)	10.2		92	(25%)	31.4	
(125, 130]	143	(19%)	11.6		68	(19%)	2.1	
(130, 135]	236	(31%)	10.3		117	(32%)	16.4	
>135	176	(23%)	10.8		86	(24%)	5.6	
BMI percentile		· · ·		0.962		· /		0.445
0-15	58	(8%)	10.5		21	(6%)	30.3	
15-85	452	(60%)	10.5		223	(61%)	16.1	
85-95	127	(17%)	10.8		64	(18%)	13.5	
95+	120	(16%)	10.8		55	(15%)	3.8	
Race/ethnicity		. ,		0.131				0.394
Hispanic	449	(59%)	11.1		203	(56%)	14.2	
White/non-Hispanic	219	(29%)	9.8		114	(31%)	11.4	
Black	14	(2%)	13.0		6	(2%)	8.0	
Asian	31	(4%)	10.6		14	(4%)	44.9	
Other	41	(5%)	9.6		25	(7%)	24.9	
Missing	3	(0.4%)	10.7		1	(0.3%)	102.2	
Ever reported allergic				0.022				0.122
rhinitis								
No	467	(62%)	10.2		238	(66%)	14.7	
Yes	206	(27%)	11.7		84	(23%)	20.6	
Missing	84	(11%)	10.7		41	(11%)	1.4	

**Table 2b.** For females, participant characteristics at year 3 and associations with fractional exhaled nitric oxide  $(F_ENO_{50})$  or percent change in  $F_ENO_{50}$  over approximately 7 years.

\* Analysis of variance (ANOVA) F-test (excluding missing categories, if applicable)

<sup>†</sup> Kruskal-Wallis test, a non-parametric alternative to ANOVA (excluding missing categories, if applicable)

			Males (N	N=809)		F	emales	(N=908)	
		Regression				Regression			
Model	Parameter*	coefficient**		EDF†	p-value	coefficient**		EDF†	p-value
Age only	s(age)			5.6	< 0.0001			5.1	< 0.0001
	te(age, bmi %)			8.4	< 0.0001			7.6	< 0.0001
Age and year 3	ti(age)			3.8	< 0.0001			3.6	< 0.0001
DIVIT %	ti(bmi %)			1.0	0.02			1.0	0.43
	ti(age, bmi %)			1.7	0.009			2.7	0.07
	Intercept		2.55		< 0.0001		2.49		< 0.0001
	White/non-Hispanic		-0.07		0.11		-0.06		0.13
$\Delta ge and race/$	Other		0.16		0.02		0.07		0.21
Age and face	s(age)			5.4	< 0.0001			5.1	< 0.0001
enimenty	s(age:Hispanic)			1.6	0.13			0.5	0.23
	s(age:White/non-Hisp)			< 0.1	0.31			< 0.1	0.51
	s(age:Other)			< 0.1	0.70			1.2	0.11
	Intercept		2.50		< 0.0001		2.45		< 0.0001
	Allergic Rhinitis		0.15		0.001		0.14		0.0005
A so and aver reported allergia whinitis at year 2	Missing		-0.01		0.83		-0.02		0.70
Age and ever reported anergic minuts at year 5	s(age)			5.5	< 0.0001			5.0	< 0.0001
	s(age:None)			< 0.1	0.40			< 0.1	0.62
	s(age:AllergicRhinitis)			2.7	0.07			< 0.1	0.51
	s(age: Missing)			1.0	0.16			< 0.1	0.74
	Intercept		2.52		< 0.0001		2.46		< 0.0001
	White/non-Hispanic		-0.10		0.02		-0.07		0.09
	Other		0.13		0.07		0.05		0.35
	Allergic Rhinitis		0.15		0.001		0.15		0.0004
	Missing		-0.02		0.79		-0.03		0.56
	te(age, bmi %)			8.4	< 0.0001			7.6	< 0.0001
D. II	Intercept		2.52		< 0.0001		2.46		< 0.0001
Full model	White/non-Hispanic		-0.10		0.02		-0.07		0.10
	Other		0.13		0.07		0.05		0.35
	Allergic Rhinitis		0.15		0.001		0.15		0.0004
	Missing		-0.02		0.79		-0.03		0.57
	ti(age)			3.8	< 0.0001			3.6	< 0.0001
	ti(bmi %)			1.0	0.01			1.0	0.40
	ti(age, bmi %)			1.5	0.02			2.7	0.07

Table 3. Summary of fitted Generalized Additive Mixed Models that model longitudinal log fractional exhaled nitric oxide ( $logF_ENO_{50}$ ) trajectories as smooth functions of time-varying age and a time-constant covariate plus a participant-level random intercept and random slope on age.

\* Smooth terms definitions: s(): penalized regression spline; ti():tensor product interaction; te():tensor product smooth.

\*\* For categorical variables; on  $log F_E NO_{50}$  scale

† Effective degrees of freedom (EDF) for the smooth term; a value of 1 indicates a linear effect, higher values indicate a higher degree of non-linearity

‡ k=5 specified in the s(age, by=race, m=1, k=5) term for improved model convergence









Supplementary materials for

"Patterns and determinants of exhaled nitric oxide trajectories in schoolchildren over a 7-year period"

#### Contents

eMethods: Additional details on the methods

- Table E1: Distribution of demographic characteristics in full study population and three subsets
- Figure E1: Selected F<sub>E</sub>NO<sub>50</sub> trajectories for participants with 6 measurements
- Table E2: Summary of fitted Generalized Additive Mixed Models presented in Figure 1
- Table E3: Bayesian Information Criteria for fitted Generalized Additive Mixed Models presented in Table 3
- Table E4: Predicted geometric mean  $F_ENO_{50}$  (and 95% CI) at ages 8 and 15
- Figure E2: Modeled sex-specific trajectories of  $F_ENO_{50}$  among participants with age at peak height velocity data
- Table E5: Predicted geometric mean  $F_ENO_{50}$  (and 95% CI) at selected ages by sex and age at peak height velocity
- Table E6: Summary of fitted Generalized Additive Mixed Models using time-varying height
- Figure E3: Modeled sex-specific trajectories of F<sub>E</sub>NO<sub>50</sub> as smooth of height by clinical factors
- Figure E4: Modeled sex-specific trajectories of  $F_ENO_{50}$  by time-varying BMI percentile
- Figure E5: Modeled sex-specific trajectories of F<sub>E</sub>NO<sub>50</sub> among participants who never reported allergic rhinitis
- Figure E6: Modeled sex-specific trajectories of  $F_ENO_{50}$  by clinical factors among participants who never reported allergic rhinitis
- Figure E7: Modeled sex-specific trajectories of  $F_ENO_{50}$  among participants who never reported wheeze or whistling in the chest
- Figure E8: Modeled sex-specific trajectories of  $F_ENO_{50}$  by clinical factors among participants who never reported wheeze or whistling in the chest

Figure E9: Modeled sex-specific trajectories of F<sub>E</sub>NO<sub>50</sub> restricting to online F<sub>E</sub>NO<sub>50</sub> measurements

Figure E10: Modeled sex-specific trajectories of F<sub>E</sub>NO<sub>50</sub> by clinical factors restricting to online F<sub>E</sub>NO<sub>50</sub>

measurements

Supplementary references Modeled sex-specific trajectories of F<sub>E</sub>NO<sub>50</sub> by clinical factors among participants

#### eMethods: Additional details on the methods

#### Measurement of Exhaled Nitric Oxide

In years 5 and 6 five 50mL/s eNO samples were collected per subject and  $F_ENO_{50}$  was calculated as the mean of the 2-3 most reproducible plateau estimates within 10%. In years 8 and 10 three 50mL/s eNO samples were collected per subject as part of a multiple flow protocol and  $F_ENO_{50}$  was calculated as the mean of 2-3 plateau estimates within 15%.

#### Statistical analysis

The intra-class correlation of repeated measurements of  $F_ENO_{50}$  was calculated using the ratio of betweenparticipant variance to the total variance from sex-specific linear mixed effects models of  $logF_ENO_{50}$  with only a random intercept for participant.

Model fit was assessed by the Bayesian Information Criterion (BIC) [1]. Generalized Additive Mixed Models (GAMMs) were estimated using restricted maximum likelihood except when reporting model fit according to the BIC [1] when we refit models using maximum likelihood.

To determine whether there was evidence for a joint smooth with age and year 3 BMI percentile (a continuous variable), we first fit models using a tensor product interaction, an ANOVA-like decomposition of the joint smooth. Given evidence of an interaction (p<0.05) in either sex, we then refit using the standard tensor product smooth which allows for more flexibility in the smooth surface. For categorical variables (race/ethnicity and year 3 ever reported allergic rhinitis), we fit a model with a single common smooth surface for age in addition to "difference" surfaces for age for each level of the categorical variable using the "by" variable approach in gamm(). This parameterization of the model permitted testing whether the smooth for a given group was

3

different from that of the overall population smooth and allows for potentially only one complex smooth surface to be estimated [2]. We imposed a first order penalty (rather than a second order penalty) on the difference smooths for identifiability, encouraging shrinkage to the mean.

(%), unless otherwise specified.		<b>D</b>	Darticipante Not	Darticipante Not
		Participants Not	Participants Not	Participants Not
	Full Study	Missing Year 3	IVISSING Year 3	Wissing Year 3 or
	Population	BMI	FENO <sub>50</sub>	Year 10 FENO50
Participants	1791	1717	1429ª	681°
Total observations	7185	6989	-	-
Observations per participant,				
median (IQR)	4 (2)	4 (2)	-	-
1	214 (11.9%)	195 (10.9%)		
2	163 (9.1%)	144 (8.0%)		
3	236 (13.2%)	223 (12.5%)		
4	344 (19.2%)	329 (18.4%)		
5	443 (24.7%)	435 (24.3%)		
6	391 (21.8%)	391 (21.8%)		
Sex				
Male	851 (47.5%)	809 (47.1%)	672 (47.0%)	318 (46.7%)
Female	940 (52.5%)	908 (52.9%)	757 (53.0%)	363 (53.3%)
Race				
Hispanic	1072 (59.9%)	1022 (59.5%)	835 (58.4%)	380 (55.8%)
White/non-Hispanic	525 (29.3%)	507 (29.5%)	445 (31.3%)	229 (33.6%)
Black	39 (2.2%)	39 (2.3%)	26 (1.8%)	10 (1.5%)
Asian	75 (4.2%)	73 (4.3%)	58 (4.1%)	25 (3.7%)
Other	71 (4.0%)	69 (4.0%)	60 (4.2%)	35 (5.1%)
Missing	9 (0.5%)	7 (0.4%)	5 (0.3%)	2 (0.3%)
Year 3 covariates				
F <sub>E</sub> NO <sub>50</sub> , ppb, median (IQR)	9.7 (7.6)	9.7 (7.6)	9.7 (7.6)	9.7 (7.5)
Missing*	362 (20.2%)	288 (16.8%)	0	0
BMI Percentile, median (IQR)	72.7 (48.7)	72.7 (48.7)	72.7 (48.7)	73.1 (47.4)
Missing*	362 (20.2%)	288 (16.8%)	0	0
Ever reported allergic rhinitis				
No	847 (47.3%)	847 (49.3%)	847 (59.3%)	418 (61.4%)
Yes	399 (22.3%)	399 (22.3%)	399 (27.9%)	178 (26.1%)
Missing*	545 (30.4%)	471 (27.4%)	183 (12.8%)	85 (12.5%)
	Table E2, Figures	Tables 2-3, Figure	Tables 1a-1b	Tables 1a-1b [column
Related tables/figures	1-2	3	[column 1]	2]

**Table E1:** Distribution of demographic characteristics in full study population and three subsets used in the analyses. N(%), unless otherwise specified.

\* Counts both participants without a year 3 visit and participants with a year 3 visit but who were missing this variable.

<sup>a</sup> Only year 3 data used.

<sup>b</sup> Only year 3 and year 10 data used.



**Figure E1.** Selected  $F_ENO_{50}$  trajectories for participants with 6 measurements and whose median detrended residuals of  $logF_ENO_{50}$  on age were at selected sex-specific percentiles (min, 25<sup>th</sup>, 50<sup>th</sup>, 90<sup>th</sup> and max).

**Table E2.** Summary of fitted Generalized Additive Mixed Models presented in Figure 1 that model longitudinal  $logF_ENO_{50}$  trajectories as smooth functions of: time-varying age (centered at age 8) with a random intercept and slope on age at the participant-level, time-varying height (centered at 130 cm) with a random intercept and slope on height, and two different parameterizations of a joint smooth of age and height with a random intercept and slope on age.

		Males (N=	851)				
Model	Smooth term	EDF*	p-value	BIC <sup>+</sup>	EDF*	p-value	BIC <sup>+</sup>
Age only	s(age)	5.7	<0.0001	5539	5.1	<0.0001	5688
Height only	s(height)	2.2	<0.0001	5544	3.8	<0.0001	5679
	te(age, height)	8.8	<0.0001	5554	7.9	<0.0001	5701
Age and height	ti(age)	1.0	0.08	5566	1.0	0.93	5713
Age and height	ti(height)	1.0	0.33		1.0	0.05	
	ti(age,height)	6.5	0.001		4.7	0.0002	

\* Effective degrees of freedom (EDF) for the smooth term; a value of 1 indicates a linear effect, higher values indicate a higher degree of non-linearity

+ Bayesian Information Criterion (BIC)

**Table E3.** Bayesian Information Criteria (BIC) for fitted Generalized Additive MixedModels presented in Table 3 that model longitudinal log fractional exhaled nitric oxide $(logF_ENO_{50})$  trajectories as smooth functions of time-varying age and a time-constantcovariate plus a participant-level random intercept and random slope on age. Model fit ismeasured by the BIC.

	B	IC
	Males	Females
Model	(N=809)	(N=908)
Age only	5338	5580
Age and year 3 BMI%		
Using a tensor product interaction for BMI%	5358	5601
Using a tensor product smooth for BMI%	5369	5616
Age and race/ethnicity	5367	5616
Age and ever reported allergic rhinitis at year 3	5367	5608
Full model		
Using a tensor product interaction for BMI%	5368	5615
Using a tensor product smooth for BMI%	5379	5630

**Table E4.** Predicted geometric mean  $F_ENO_{50}$  (and 95% CI) at ages 8 and 15, as well as the percent difference from age 8to age 15, from the sex-specific model with only a smooth function of age and for specific covariate combinations fromthe sex-specific "final" models including a joint smooth of age and year 3 BMI percentile and adjustments forrace/ethnicity and allergic rhinitis status at year 3.

		Year 3 child characteristics			
		(BMI%, Race/Ethnicity, Allergic	Age 8,	Age 15,	Percent
Sex	Model	rhinitis)	Geo. Mean	Geo. Mean	Difference
	s(age) only				
	model		10.6 (10.1, 11.2)	16.5 (15.4,17.6)	54.9 (44.8, 65.8)
		15%, Hispanic, No	10.5 (9.3, 11.9)	18.9 (16.5, 21.7)	80.0 (58.5, 104.4)
		15%, White/non-Hispanic, No	9.5 (8.4, 10.8)	17.1 (14.9, 19.7)	80.0 (58.5, 104.4)
		15%, Other, No	12.0 (10.1, 14.2)	21.6 (18.0, 25.8)	80.0 (58.5, 104.4)
		15%, Hispanic, Yes	12.2 (10.7, 13.9)	21.9 (19.0, 25.4)	80.0 (58.5, 104.4)
Mala		15%, White/non-Hispanic, Yes	11.0 (9.7, 12.6)	19.8 (17.2, 22.9)	80.0 (58.5, 104.4)
wale	Final	15%, Other, Yes	13.9 (11.7, 16.5)	25.0 (20.8, 30.0)	80.0 (58.5, 104.4)
	model	95%, Hispanic, No	10.4 (9.5, 11.2)	15.0 (13.7, 16.5)	45.1 (33.5, 57.7)
		95%, White/non-Hispanic, No	9.4 (8.5, 10.3)	13.6 (12.2, 15.1)	45.1 (33.5, 57.7)
		95%, Other, No	11.8 (10.2, 13.7)	17.1 (14.7, 20.0)	45.1 (33.5, 57.7)
		95%, Hispanic, Yes	12.0 (10.9, 13.3)	17.4 (15.6, 19.4)	45.1 (33.5, 57.7)
		95%, White/non-Hispanic, Yes	10.8 (9.7, 12.1)	15.7 (14.0, 17.7)	45.1 (33.5, 57.7)
		95%, Other, Yes	13.6 (11.7, 15.9)	19.8 (16.9, 23.3)	45.1 (33.5, 57.7)
	s(age) only				
	model		10.7 (10.2, 11.2)	12.6 (11.9, 13.4)	17.8 (11.0, 25.0)
		15%, Hispanic, No	10.1 (9.1, 11.1)	13.2 (11.7, 14.9)	31.0 (17.3, 46.3)
		15%, White/non-Hispanic, No	9.4 (8.5, 10.4)	12.3 (10.9, 14.0)	31.0 (17.3, 46.3)
		15%, Other, No	10.6 (9.3, 12.0)	13.9 (12.0, 16.1)	31.0 (17.3, 46.3)
		15%, Hispanic, Yes	11.7 (10.4, 13.0)	15.3 (13.4, 17.4)	31.0 (17.3, 46.3)
Famala		15%, White/non-Hispanic, Yes	10.9 (9.7, 12.2)	14.3 (12.5, 16.3)	31.0 (17.3, 46.3)
remale	Final	15%, Other, Yes	12.3 (10.7, 14.0)	16.1 (13.8, 18.7)	31.0 (17.3, 46.3)
	model	95%, Hispanic, No	10.8 (10.0, 11.6)	12.2 (11.2, 13.4)	13.7 (4.9, 23.3)
		95%, White/non-Hispanic, No	10.1 (9.2, 11.0)	11.4 (10.3, 12.7)	13.7 (4.9, 23.3)
		95%, Other, No	11.3 (10.1, 12.8)	12.9 (11.3, 14.7)	13.7 (4.9, 23.3)
		95%, Hispanic, Yes	12.5 (11.4, 13.7)	14.2 (12.8, 15.7)	13.7 (4.9, 23.3)
		95%, White/non-Hispanic, Yes	11.6 (10.5, 12.9)	13.2 (11.8, 14.9)	13.7 (4.9, 23.3)
		95%, Other, Yes	13.1 (11.6, 14.9)	14.9 (13.0, 17.1)	13.7 (4.9, 23.3)



**Figure E2.** Population average sex-specific trajectories of  $F_ENO_{50}$  (solid lines) and 95% Confidence Intervals (dashed lines) in subset of participants with data on age at peak height velocity (N=288 males, N=323 females) modeled as a smooth function of age only, for males (black) or females (grey). Analyses performed using  $logF_ENO_{50}$  with results here presented using back-transformed values on an axis scaled using natural log.

**Table E5.** Predicted geometric mean F<sub>E</sub>NO<sub>50</sub> (and 95% CI) at selected ages, from the sex-specific model with a joint smooth of age and year 3 BMI percentile by age at peak height velocity (dichotomized based on sex-specific median) and adjustments for race/ethnicity and allergic rhinitis status at year 3.

	Age at Peak Height Velocity								
		Early		Late					
Age (yrs)	Male	Female	Male	Female					
9	10.3 (8.9, 11.8)	10.2 (8.9, 11.6)	10.1 (8.8, 11.5)	10.3 (9.2, 11.5)					
10	11.2 (9.8, 12.9)	10.7 (9.4, 12.2)	10.6 (9.3, 12.1)	10.9 (9.7, 12.1)					
12	13.4 (11.6, 15.4)	11.7 (10.1, 13.5)	11.9 (10.4, 13.7)	11.8 (10.4, 13.3)					
14	15.9 (13.6 <i>,</i> 18.6)	11.9 (10.2, 13.9)	13.6 (11.8, 15.7)	13.6 (11.9, 15.4)					
16	18.9 (15.8, 22.7)	11.8 (9.7, 14.2)	14.6 (12.3, 17.4)	12.1 (10.2, 14.3)					

				Females (N=908)					
		Regression				Regression			
Model	Parameter*	coefficient **	EDF <sup>+</sup>	p-value	BIC	coefficient **	EDF <sup>+</sup>	p-value	BIC
Height only	s(height)		2.0	<0.0001	5339		3.7	<0.0001	5571
	te(height, bmi)		5.5	<0.0001	5350		6.2	<0.0001	5595
Height and year 3	ti(height)		1.9	< 0.0001	5366		3.4	<0.0001	5610
BMI %	ti(bmi)		1.0	0.0008			1.0	0.89	
	ti(height, bmi)		1.0	0.03			1.0	0.78	
	Intercept	2.55		<0.0001	5370	2.50		<0.0001	5607
	White/non-Hispanic	-0.08		0.08		-0.07		0.11	
Height and race/	Other	0.15		0.04		0.06		0.33	
ethnicity <sup>‡</sup>	s(height)		1.3	<0.0001			3.5	<0.0001	
etimicity	s(height:Hispanic)		<0.1	0.31			1.2	0.15	
	s(height:White/non-Hisp)		1.4	0.18			<0.1	0.99	
	s(height:Other)		<0.1	0.72			<0.1	0.36	
	Intercept	2.50		<0.0001	5366	2.45		<0.0001	5596
	Allergic Rhinitis	0.15		0.001		0.15		0.0002	
Height and	Missing	-0.01		0.92		-0.03		0.63	
ever reported allergic rhinitis at	s(height)		1.0	<0.0001			3.7	<0.0001	
year 3	s(height:None)		2.5	0.04			<0.1	0.99	
	s(height:AllergicRhinitis)		<0.1	0.61			<0.1	0.91	
	s(height: Missing)		1.5	0.12			<0.1	0.56	
	Intercent	2.53		<0.0001	5360	2.47		<0.0001	5606
	White/non-Hispanic	-0.11		0.01		-0.08		0.05	
	Othor	0.12		0.10		0.04		0.45	
	Allergic Rhinitis	0.15		0.001		0.16		0.0002	
	Allergic Ministra	-0.01		0.87		-0.04		0.52	
	te(height hmi)		5.0	<0.0001			6.3	<0.0001	
Full model	Intercept	2.53		<0.0001	5376	2.47		<0.0001	5621
	White/non-Hispanic	-0.11		0.01		-0.08		0.05	
	Other	0.12		0.10		0.04		0.46	
	Allergic Rhinitis	0.14		0.001		0.16		0.0002	
	Missing	-0.01		0.87		-0.04		0.52	
	ti(height)		1.9	<0.0001			3.4	<0.0001	
	ti(bmi)		1.0	0.0005			1.0	0.87	
	ti(height, bmi)		1.2	0.03			1.0	0.71	

**Table E6.** Summary of fitted Generalized Additive Mixed Models that model longitudinal log F<sub>E</sub>NO<sub>50</sub> trajectories as smooth functions of time-varying **height** and a time-constant covariate. Model fit is measured by the Bayesian Information Criterion (BIC).

\* Smooth terms definitions: s(): penalized regression spline; ti():tensor product interaction; te():tensor product smooth.

\*\* For categorical variables; on logF<sub>E</sub>NO<sub>50</sub> scale

<sup>†</sup> Effective degrees of freedom (EDF) for the smooth term; a value of 1 indicates a linear effect, higher values indicate a higher degree of non-linearity

‡ k=5 specified in the s(age, by=race, m=1, k=5) term for improved model convergence



**Figure E3.** Modeled sex-specific trajectory of F<sub>E</sub>NO<sub>50</sub> as a joint smooth of **height** and year 3 BMI percentile or as smooths of **height** that vary by race/ethnicity or ever reported allergic rhinitis at year 3.



**Figure E4.** Modeled sex-specific trajectory of  $F_ENO_{50}$  as a joint smooth of age and time-varying BMI percentile for males (a) or females (b) (N=851 males, N=940 females), or a joint smooth of age and year 3 BMI percentile for males (c) or females (d) (N=809 males, N=908 females). The contour lines labels refer to predicted geometric mean  $F_ENO_{50}$  in ppb. Analyses performed using log $F_ENO_{50}$  with results here presented using back-transformed values on an axis scaled using natural log.



**Figure E5.** Modeled sex-specific trajectory of  $F_ENO_{50}$  as a: (a) smooth function of age only<sup>\*</sup>, (b) a smooth function of height only<sup>\*</sup>, or a joint smooth of age and height for males (c) or females (d) among participants who never reported allergic rhinitis through year 10 of the study (N=512 males, N=550 females).



**Figure E6.** Modeled sex-specific trajectory of  $F_ENO_{50}$  as a joint smooth of age and year 3 BMI percentile or as smooths of age that vary by race/ethnicity among participants who never reported allergic rhinitis through year 10 of the study and without missing year 3 BMI percentile (N=485 males, N=527 females).



**Figure E7.** Modeled sex-specific trajectory of  $F_ENO_{50}$  as a: (a) smooth function of age only<sup>\*</sup>, (b) a smooth function of height only<sup>\*</sup>, or a joint smooth of age and height for males (c) or females (d) among participants who never reported wheeze or whistling in the chest through year 10 of the study (N=735 males, N=791 females).



**Figure E8.** Modeled sex-specific trajectory of  $F_ENO_{50}$  as a joint smooth of age and year 3 BMI percentile or as smooths of age that vary by race/ethnicity among participants who never reported wheeze or whistling in the chest through year 10 of the study and without missing year 3 BMI percentile (N=697 males, N=768 females).



**Figure E9.** Modeled sex-specific trajectory of  $F_ENO_{50}$  as a: (a) smooth function of age only<sup>\*</sup>, (b) a smooth function of height only<sup>\*</sup>, or a joint smooth of age and height for males (c) or females (d) restricting to online  $F_ENO_{50}$  measurements (N=740 males, N=818 females).



**Figure E10.** Modeled sex-specific trajectory of  $F_ENO_{50}$  as a joint smooth of age and year 3 BMI percentile or as smooths of age that vary by race/ethnicity among participants without missing year 3 BMI percentile and restricting to online  $F_ENO_{50}$  measurements (N=700 males, N=788 females).

# Supplementary references

1. Gurka MJ. Selecting the best linear mixed model under REML. *The American Statistician* 2006: 60(1): 19-

26.

2. Wood SN. Generalized additive models: an introduction with R. CRC press, 2017.